Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of rotenone in preparation of medicine for treating systemic lupus erythematosus

A systemic technology for lupus erythematosus, applied in drug combinations, antineoplastic drugs, pharmaceutical formulations, etc., can solve problems such as disordered mitochondrial function, damaged protein nucleic acid, increased ROS, etc., to inhibit the formation of lymph node tumors, inhibit abnormal activation, and inhibit Effects of an enlarged spleen

Inactive Publication Date: 2018-11-16
NANJING CHILDRENS HOSPITAL
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Rotenone is one of the classic inhibitors of Complex I on the mitochondrial respiratory chain. It is a highly effective inhibitor of NADH dehydrogenase to ubiquinone oxidoreductase, which can disrupt mitochondrial function, increase the production of ROS, and oxidatively damage proteins, lipids, and nucleic acids. , which leads to obstacles in the use of oxygen by cells and cannot produce enough energy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of rotenone in preparation of medicine for treating systemic lupus erythematosus
  • Application of rotenone in preparation of medicine for treating systemic lupus erythematosus
  • Application of rotenone in preparation of medicine for treating systemic lupus erythematosus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1 Rotenone inhibits the production of antinuclear antibodies in the serum of MRL / Ipr lupus mice

[0022] The mice in the model group, drug-dosed group, and control group that were fed to the 33rd week were taken separately, and 8 mice were taken from each group. After the mice were anesthetized, blood was taken from the inferior vena cava, placed in an anticoagulant tube, and allowed to stand at room temperature for 30 minutes. Minutes later, the serum was centrifuged and the anti-dsDNA-antibody kit was used to detect the concentration of antinuclear antibody in the serum. For specific operation steps, refer to the kit instruction manual. The result is as figure 1 As shown, the average concentration of antinuclear antibody in the mouse serum of the control group, the model group and the drug-added group were 424IU / mL, 1602IU / mL and 681IU / mL, respectively, and the concentration of antinuclear antibody in the mouse serum of the model group was significantly higher...

Embodiment 2

[0023] Example 2 Rotenone alleviates myocardial function damage in MRL / Ipr lupus mice

[0024] The mice in the model group, drug-dosed group, and control group that were fed to the 33rd week were taken separately, and 8 mice were taken from each group. After the mice were anesthetized, blood was taken from the inferior vena cava, placed in an anticoagulant tube, and allowed to stand at room temperature for 30 minutes. Minutes later, the serum was centrifuged, and the concentrations of lactate dehydrogenase (LDH) and aspartate aminotransferase (AST) in the serum were detected by a biochemical analyzer, and the results were as follows: figure 2 and image 3 As shown, the average concentration of LDH in the mouse serum of the control group, the model group and the drug-added group was 577U / L, 1312U / L and 487U / L respectively, and the average concentration of AST in the mouse serum of the control group, the model group and the drug-added group Concentrations were 73U / L, 223U / L an...

Embodiment 3

[0025] Example 3 Rotenone inhibits abnormal activation of spleen B lymphocytes and splenomegaly in MRL / Ipr lupus mice

[0026] The mice in the model group, drug-dosed group, and control group that were fed to the 33rd week were taken respectively, 5 mice were taken from each group, the spleens of the mice were separated, and the size of the spleens was observed, as shown in Fig. Figure 4 As mentioned above, the spleens of the mice in the dosing group were significantly smaller than those in the model group. The spleen was ground and passed through a 200-mesh sieve, washed with pre-cooled PBS to obtain a single cell suspension, and the erythrocytes were lysed with erythrocyte lysate, stained with different fluorescently labeled B220 antibodies and CD69 antibodies, and incubated at 4°C in the dark for 30 minutes. After washing with PBS for 3 times, the number of B220 and CD69 double-positive cells and the ratio of B220 and CD69 double-positive cells to all spleen cells were det...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of rotenone in the preparation of a medicine for treating systemic lupus erythematosus and belongs to the field of Chinese medicine production. Rotenone can inhibit generation of antinuclear antibodies for lupus mice, alleviate myocardial damage of lupus mice, inhibit abnormal activation of B lymphocyte and splenomegaly for lupus mice and inhibit formation of lymph node tumor for lupus mice. Therefore, the invention provides a new candidate drug for treating systemic lupus erythematosus.

Description

technical field [0001] The invention relates to the application of rotenone in the preparation of medicines, in particular to the application of rotenone in the preparation of medicines for treating systemic lupus erythematosus. Background technique [0002] Systemic lupus erythematosus (SLE) is a multisystem chronic relapsing autoimmune disease with complex clinical manifestations, including damage to multiple organs, including the heart, lungs, skin, and immune system. The main pathological features of SLE are the production of autoantibodies and the precipitation of immune complexes. A variety of autoantibodies can be detected in the patient's serum, among which antinuclear antibodies are the main representative. There are about 1 million SLE patients in my country, the prevalence rate is the second in the world, and more than 50% of the patients have blood system involvement. Given that SLE involves complex mechanisms of immune system disorders, genetics, and environmen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/352A61P37/02A61P17/06A61P35/00A61P43/00
CPCA61K31/352A61P17/06A61P35/00A61P37/02A61P43/00
Inventor 公伟贾占军张爱华张玥黄松明麻昊旸吴炆晓
Owner NANJING CHILDRENS HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com